The Food and Drug Administration issued a direct final rule on 21 September 2026 that replaces references to animal testing with the term “nonclinical studies” throughout its drug application regulations, according to The First Cohort. The outlet reported that Congress removed the statutory animal-testing requirement for new drugs back in 2022, meaning the agency’s own rulebook has been out of step with the law for four years.
The FDA’s rule falls under what is known as a direct final rule process, which agencies use for changes they consider noncontroversial, since it skips the standard comment period unless someone objects. That procedural choice matters here because the substance of the rule is limited. The First Cohort’s reporting states plainly that the update changes vocabulary in the regulatory text rather than the bar a drug must clear, the evidentiary standard, the cost of compliance, or any mandate on sponsors.
What actually changed and what did not
Congress amended the Food, Drug, and Cosmetic Act in 2022 to end the requirement that new drugs undergo animal testing before human trials, opening the door to alternative methods such as organ-on-a-chip technology and computer modelling. That legislative change took effect immediately upon passage. The FDA’s 2026 rule brings the agency’s internal regulations into alignment with that statute by swapping out the word “animal” for “nonclinical” in the relevant sections, according to the same First Cohort report.
The report does not indicate that the rule imposes any new requirement on drug sponsors to use non-animal methods, nor does it lower or raise the evidentiary threshold the FDA applies when reviewing an application. In other words, a sponsor that continues to rely on animal studies today can do so under the new rule exactly as it could before the rule was issued, and a sponsor that wants to submit organ-chip or computational data can already do so under the 2022 statute regardless of whether the FDA’s regulations use the word “animal” or “nonclinical.”
Kyle Diamantas, identified in the report as an FDA official connected to the drug evaluation process, was named in the First Cohort’s coverage of the rule’s rollout, though the report attributes no specific quote or claim to him beyond his association with the announcement.
Why the four-year gap raises questions
The four-year lag between the statutory change and the regulatory update invites a fair question about institutional priorities. If the substantive requirement changed in 2022, why did it take until September 2026 for the FDA to update the text that regulated industry and the public actually read? A direct final rule is meant for housekeeping matters, and the FDA’s own framing treats this instance as exactly that: a cleanup of language that had lagged behind the law. Whether that framing satisfies scrutiny depends on whether the agency can explain the delay, which the available reporting does not address.
How the outlets framed it
The FDA’s own announcement and outlets echoing it, including The First Cohort’s headline framing, present the rule as the agency finally advancing alternatives to animal testing and modernising its rulebook to match congressional intent. A closer reading of the same First Cohort report undercuts that framing, since the piece itself states the rule changes no evidentiary standards, no costs, and no requirements for sponsors. The gap between the celebratory framing of “advancing alternatives” and the article’s own admission that nothing substantive moved is the story. It suggests regulators may be claiming credit for a legislative act Congress completed years earlier, while doing the minimum necessary to make the paperwork consistent.
Readers who track regulatory announcements for signals about industry costs or approval pathways should treat this rule as a language update rather than a policy shift. The practical effect on how drugs are tested and approved in the United States appears unchanged from what Congress established in 2022.
